New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer
Diana Lüftner1, Matthias Peipp2
1Medizinische Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie, Charité, Universitätsmedizin Berlin, Berlin, Germany.
Abstract:
Despite therapeutic gains in the treatment of HER2-positive (HER2: human epidermal growth factor receptor 2) advanced/metastatic breast cancer, there remains an urgent need for more effective treatment options. At present, there is no definitive approved standard therapy beyond second-line treatment. One of the major challenges is overcoming treatment resistance. Depending on the underlying resistance mechanism, different strategies are being pursued for new innovative treatment concepts in HER2-positive breast cancer. Specifically designed antibodies for targeted therapy are one important focus to successfully meet these challenges. Trastuzumab deruxtecan (T-DXd, DS-8201a), an optimised antibody drug conjugate (ADC) is in clinical trials, showing promising outcomes in patients with advanced, nonoperable or metastatic HER2-positive breast cancer who had already undergone intensive prior treatment. Based on this data, T-DXd has already been approved in the US and Japan for HER2-positive advanced nonoperable and metastatic breast cancer - in the US after at least two prior anti-HER2 targeted treatment lines and in Japan after prior chemotherapy. T-DXd represents successful "antibody engineering". Since the beginning of the year, T-DXd has also been approved in Europe as monotherapy for inoperable or metastatic HER2-positive breast cancer in patients who are pretreated with at least two anti-HER2 directed therapies. This paper presents strategies for improving treatment options in advanced nonoperable and metastatic HER2-positive breast cancer, with the development of T-DXd as an example.
Insights
New antibody drug conjugates like trastuzumab deruxtecan offer improved treatment for advanced HER2-positive breast cancer, addressing resistance and unmet needs beyond second-line therapy.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Advanced/metastatic HER2-positive breast cancer lacks effective treatments beyond second-line therapy.
- Treatment resistance is a major challenge in managing HER2-positive breast cancer.
- Targeted therapies, particularly antibody-drug conjugates, show promise for overcoming resistance.
Purpose of the Study:
- To present strategies for improving treatment options in advanced HER2-positive breast cancer.
- To highlight the development and efficacy of trastuzumab deruxtecan (T-DXd) as an innovative treatment.
- To discuss overcoming treatment resistance in HER2-positive breast cancer.
Main Methods:
- Review of clinical trial data for trastuzumab deruxtecan (T-DXd).
- Analysis of T-DXd's efficacy in patients with heavily pretreated advanced/metastatic HER2-positive breast cancer.
- Discussion of antibody engineering strategies for targeted cancer therapy.
Main Results:
- Trastuzumab deruxtecan (T-DXd) demonstrates promising outcomes in patients with advanced, nonoperable, or metastatic HER2-positive breast cancer.
- T-DXd has received regulatory approval in the US, Japan, and Europe for specific patient populations.
- The drug represents a significant advancement in antibody-drug conjugate technology.
Conclusions:
- Trastuzumab deruxtecan (T-DXd) offers a new therapeutic option for patients with advanced HER2-positive breast cancer, particularly those resistant to prior treatments.
- Antibody engineering and targeted therapies are crucial for developing innovative treatment concepts.
- Further strategies are needed to address the ongoing challenges in HER2-positive breast cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...